Thalidomide
- Generic Name
- Thalidomide
- Brand Names
- Thalomid, Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed
- Drug Type
- Small Molecule
- Chemical Formula
- C13H10N2O4
- CAS Number
- 50-35-1
- Unique Ingredient Identifier
- 4Z8R6ORS6L
- Background
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence.
- Indication
Thalidomide is primarily used for the acute treatment and maintenance therapy to prevent and suppress the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).
- Associated Conditions
- Aphthous Stomatitis, Chronic Graft-Versus-Host Disease, Erythema Nodosum Leprosum, Multiple Myeloma (MM), Primary Amyloidosis, Uremic Pruritus, Waldenström's Macroglobulinemia (WM), Moderate Erythema nodosum leprosum, Refractory Graft versus host disease, Severe Erythema nodosum leprosum, Treatment naive multiple myeloma
- Associated Therapies
- -
Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-01-09
- Lead Sponsor
- Rush University Medical Center
- Target Recruit Count
- 5
- Registration Number
- NCT00014443
- Locations
- 🇺🇸
Rush Cancer Institute at Rush University Medical Center, Chicago, Illinois, United States
Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy
- Conditions
- Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- Nuvance Health
- Registration Number
- NCT00046826
- Locations
- 🇺🇸
Whittingham Cancer Center at Norwalk Hospital, Norwalk, Connecticut, United States
🇺🇸Carl and Dorothy Bennett Cancer Center at Stamford Hospital, Stamford, Connecticut, United States
Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-10-17
- Lead Sponsor
- University of Maryland, Baltimore
- Registration Number
- NCT00049374
- Locations
- 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸St. Vincent's Comprehensive Cancer Center - Manhattan, New York, New York, United States
Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer
- Conditions
- Kidney Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-11
- Lead Sponsor
- Fox Chase Cancer Center
- Registration Number
- NCT00025519
Thalidomide in Treating Patients With Gynecologic Sarcomas
- Conditions
- Endometrial CancerSarcoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- New York University Cancer Institute
- Registration Number
- NCT00006005
- Locations
- 🇺🇸
North Shore University Hospital, Manhasset, New York, United States
🇺🇸New York Medical College, Valhalla, New York, United States
🇺🇸Mount Sinai School of Medicine, New York, New York, United States
Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma
- Conditions
- Intraocular MelanomaMelanoma (Skin)
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00005815
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer
- Conditions
- Ovarian Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00016224
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
- Conditions
- Gastrointestinal Carcinoid TumorIslet Cell TumorLung CancerNeoplastic Syndrome
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00027638
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer
- Conditions
- Kidney Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2009-02-05
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00005966
- Locations
- 🇵🇪
Instituto de Enfermedades Neoplasicas, Lima, Peru
🇺🇸Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸CCOP - St. Vincent Hospital Cancer Center, Green Bay, Green Bay, Wisconsin, United States
Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- California Cancer Consortium
- Registration Number
- NCT00022607
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.